ValuEngine upgraded shares of Cytori Therapeutics (NASDAQ:CYTX) from a strong sell rating to a sell rating in a research report report published on Friday.

CYTX has been the topic of a number of other reports. Maxim Group set a $5.00 target price on Cytori Therapeutics and gave the stock a buy rating in a research report on Monday, November 13th. Zacks Investment Research raised Cytori Therapeutics from a sell rating to a hold rating in a research report on Tuesday, January 2nd. Finally, B. Riley reissued a hold rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.

Shares of Cytori Therapeutics (NASDAQ CYTX) opened at $0.39 on Friday. Cytori Therapeutics has a 1 year low of $0.22 and a 1 year high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. The business had revenue of $1.77 million for the quarter, compared to the consensus estimate of $2.04 million. During the same period last year, the business earned ($0.26) earnings per share. equities research analysts anticipate that Cytori Therapeutics will post -0.62 EPS for the current year.

In other Cytori Therapeutics news, major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the transaction, the insider now owns 5,496,655 shares in the company, valued at $2,088,728.90. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.90% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after purchasing an additional 275,653 shares during the period. Sabby Management LLC lifted its stake in Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 355,504 shares during the period. Finally, Perkins Capital Management Inc. lifted its stake in Cytori Therapeutics by 134.0% during the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after purchasing an additional 1,223,046 shares during the period. Hedge funds and other institutional investors own 10.82% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cytori Therapeutics (CYTX) Upgraded to “Sell” by ValuEngine” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.